Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.78 |
| ▸ | MEN1 | O00255 | 3/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | POLB | P06746 | 4/20 | 0.70 |
| ▸ | HPGD | P15428 | 5/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12591836 | 0.95 | KMT2A (0.71) | KMT2AALDH1A1MEN1LMNASMN1; SMN2 | |
| SCHEMBL17465250 | 0.94 | KMT2A (0.85) | KMT2AALDH1A1MEN1LMNASMN1; SMN2 | |
| SCHEMBL10495198 | 0.93 | ALDH1A1 (0.89) | KMT2AALDH1A1MEN1LMNASMN1; SMN2 | |
| SCHEMBL19226699 | 0.87 | KMT2A (0.61) | KMT2AALDH1A1MEN1LMNASMN1; SMN2 | |
| SCHEMBL10724841 | 0.87 | POLB (0.81) | KMT2AALDH1A1MEN1LMNAPOLB | |
| SCHEMBL23707094 | 0.87 | POLB (0.61) | KMT2AALDH1A1MEN1LMNASMN1; SMN2 | |
| SCHEMBL14847023 | 0.87 | POLB (0.61) | KMT2AALDH1A1MEN1LMNASMN1; SMN2 | |
| SCHEMBL12089434 | 0.86 | ALDH1A1 (0.78) | KMT2AALDH1A1MEN1LMNASMN1; SMN2 | |
| SCHEMBL10169258 | 0.86 | ALDH1A1 (0.96) | KMT2AALDH1A1MEN1LMNASMN1; SMN2 | |
| SCHEMBL1104737 | 0.86 | ALDH1A1 (0.90) | KMT2AALDH1A1MEN1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-20230142739-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | UNIV CALIFORNIA (US) | 2023-05-11 | — | — | US | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | ARRAY BIOPHARMA INC (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3204360-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | NOVARTIS AG (CH) | 2020-04-28 | — | — | US | disclosed |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-10259811-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | GENENTECH, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090143381-A1 | MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-06-04 | — | — | US | disclosed |
| US-7247641-B2 | Compounds, derivatives, compositions, preparation and uses | MGI GP, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | KMT2A 4505/4885ALDH1A1 983/4885MEN1 4307/4885 |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | JAK2, JAK1, JAK3 | KMT2A 1888/4885ALDH1A1 2375/4885MEN1 3155/4885 |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | KMT2A 2222/4885ALDH1A1 1780/4885MEN1 3138/4885 |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | RHEB, KRAS, NRAS | KMT2A 2481/4885ALDH1A1 3621/4885MEN1 254/4885 |
| US-10259811-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | KMT2A 1865/4885ALDH1A1 4260/4885MEN1 3091/4885 |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | KMT2A 1865/4885ALDH1A1 4260/4885MEN1 3091/4885 |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, PRKCSH | KMT2A 1093/4885ALDH1A1 649/4885MEN1 1943/4885 |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | MYOF, NGF, MUSK | KMT2A 4503/4885ALDH1A1 921/4885MEN1 4366/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | KMT2A 3149/4885ALDH1A1 3277/4885MEN1 169/4885 |
| US-20090143381-A1 | MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS | CFTR, ABCB1, ABCC2 | KMT2A 4349/4885ALDH1A1 1985/4885MEN1 4755/4885 |
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | MAP3K1, MAP3K3, MAP3K2 | KMT2A 851/4885ALDH1A1 3807/4885MEN1 1758/4885 |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | KMT2A 141/4885ALDH1A1 3322/4885MEN1 1745/4885 |
| US-20230142739-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | HSPBP1, HSPA8, HSPH1 | KMT2A 3385/4885ALDH1A1 3889/4885MEN1 3934/4885 |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | KMT2A 1888/4885ALDH1A1 2375/4885MEN1 3155/4885 |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LCK | KMT2A 1229/4885ALDH1A1 4570/4885MEN1 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.